Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2013122821) SUBSTITUTED CYCLOPROPYL COMPOUNDS USEFUL AS GPR119 AGONISTS
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/2013/122821 International Application No.: PCT/US2013/025241
Publication Date: 22.08.2013 International Filing Date: 08.02.2013
IPC:
C07D 401/04 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
401
Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
02
containing two hetero rings
04
directly linked by a ring-member-to-ring- member bond
Applicants:
LIU, Ping [CN/US]; US (US)
SZEWCZYK, Jason, W. [US/US]; US (US)
WANG, Liping [US/US]; US (US)
WOOD, Harold, B. [US/US]; US (US)
ZHU, Cheng [CN/US]; US (US)
EDMONDSON, Scott, D. [US/US]; US (US)
MERCK SHARP & DOHME CORP. [US/US]; 126 East Lincoln Avenue Rahway, New Jersey 07065-0907, US
Inventors:
LIU, Ping; US
SZEWCZYK, Jason, W.; US
WANG, Liping; US
WOOD, Harold, B.; US
ZHU, Cheng; US
EDMONDSON, Scott, D.; US
Common
Representative:
MERCK SHARP & DOHME CORP.; 126 East Lincoln Avenue Rahway, New Jersey 07065-0907, US
Priority Data:
61/598,46414.02.2012US
Title (EN) SUBSTITUTED CYCLOPROPYL COMPOUNDS USEFUL AS GPR119 AGONISTS
(FR) COMPOSÉS CYCLOPROPYLÉS SUBSTITUÉS UTILES COMME AGONISTES DE GPR119
Abstract:
(EN) Substituted cyclopropyl compounds of the formula I: and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. The compounds are useful as agonists of the G-protein coupled receptor GPR-119. Pharmaceutical compositions and methods of treatment are also included.
(FR) L'invention concerne des composés cyclopropylés substitués de la formule I : et des sels pharmaceutiquement acceptables de ceux-ci qui sont utiles pour le traitement ou la prévention de diabète de type 2 et d'états similaires. Les composés sont utiles en tant qu'agonistes du récepteur GPR-119 couplé à la protéine G. L'invention concerne également des compositions pharmaceutiques et des procédés de traitement.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)